CompletedNot Applicable

PRISM for Depression and Anxiety in Young Adults With Cancer

United States13 participantsStarted 2024-09-06

Plain-language summary

This research study is being done to test the feasibility of an existing supportive program (PRISM) to address psychological symptoms (i.e., depressive and anxiety symptoms) that young adult participants diagnosed with cancer or desmoid tumor may experience. The name of the intervention used in this research study is: -Promoting Resilience in Stress Management (PRISM) Program

Who can participate

Age range18 Years – 39 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 18-39 years of age
✓. Speak and comprehend English sufficiently to be able to complete study procedures and participate in the program in English\*
✓. Have been diagnosed with cancer or desmoid tumor at least 6 or more weeks ago
✓. Currently receiving treatment or has completed treatment for cancer or desmoid tumor no more than 6 months ago
✓. Score 10-24 (with question #9 not endorsed, or 0) on the PHQ-9 (Kroenke et al., 1999) or/and score 10-21 on the GAD-7 (Spitzer et al., 2006) during the initial screening assessment.

Exclusion criteria

✕. Adults unable to consent, individuals who are not yet adults (age \<18), pregnant women, and prisoners.
✕. Individuals who score less than 10 on both PHQ-9 and GAD-7.
✕. Individuals who are diagnosed with cancer less than 6 weeks at the time of screening (we will be able to approach them again after 6 weeks since diagnosis has passed), or those who completed treatment more than 6 months ago will also be ineligible for this study; they will be offered resources for support, if desired.
✕≥ 18 years of age
✕A friend or family member invited by the study participant to join the 6th PRISM session

What they're measuring

Rate of PRISM Intervention Completion

Timeframe: Up to 12 weeks

Rate of Study Assessment Completion

Timeframe: Up to 12 weeks

Participant Satisfaction

Timeframe: At final intervention session, up to 6 weeks

Trial details

NCT IDNCT06502483

SponsorDana-Farber Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02-01

View on ClinicalTrials.gov More Cancer Diagnosis trials